METHOD OF TREATING PANCREATIC CANCER
A therapeutic method for treating pancreatic cancer is disclosed comprising administering to a patient in need of treatment a ruthenium complex salt.
1 . A method of treating pancreatic cancer comprising administering to a patient in need of the treatment a therapeutically effective amount of a pharmaceutically acceptable salt of trans-[tetrachlorobis(1H-indazole)ruthenate(III)].
2 . The method according to claim 1 , wherein said pharmaceutically acceptable salt is an alkali metal salt of trans-[tetrachlorobis(1H-indazole)ruthenate(III)].
3 . The method of claim 2 , wherein said alkali metal salt of trans-[tetrachlorobis(1H-indazole)ruthenate(III)] is sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)].
4 . A method of treating a refractory pancreatic cancer comprising administering to a patient in need of the treatment a therapeutically effective amount of a pharmaceutically acceptable salt of trans-[tetrachlorobis(1H-indazole)ruthenate(III)].
5 . The method of claim 4 , wherein said patient is refractory to a treatment comprising one or both of gemcitabine and erlotinib.
6 . The method of claim 4 , wherein said patient was previously treated with and not responsive to a treatment comprising one or both of gemcitabine and erlotinib.
7 . The method of claim 4 , wherein said patient has pancreatic cancer relapsing after a previous treatment comprising one or both of gemcitabine and erlotinib.
8 . The method of claim 4 , wherein said patient previously received a treatment comprising gemcitabine.
9 . The method according to claim 4 , wherein said patient previously received a treatment comprising erlotinib.
10 . The method according to claim 2 , wherein said pharmaceutically acceptable salt is an alkali metal salt of trans-[tetrachlorobis(1H-indazole)ruthenate(III)].
11 . The method of claim 10 , wherein said alkali metal salt of trans-[tetrachlorobis(1H-indazole)ruthenate(III)] is sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)].